Article:
Li, R, Adami, A, Chang, C-C et al. (3 more authors) (2020) Serum Acylglycerols Inversely Associate with Muscle Oxidative Capacity in Severe COPD. Medicine & Science in Sports & Exercise. ISSN 0195-9131

https://doi.org/10.1249/mss.0000000000002441

Serum Acylglycerols Inversely Associate with Muscle Oxidative Capacity in Severe COPD

*Rongsong Li[1], *Alessandra Adami[2,3], Chih-Chiang Chang[4], Chi-Hong Tseng[4], Tzung K. Hsiai[4], Harry B. Rossiter[3,5]

[1] College of Health Science and Environmental Engineering, Shenzhen Technology University, Shenzhen, Guangdong, China

[2] Department of Kinesiology, University of Rhode Island, Kingston, RI

[3] Rehabilitation Clinical Trials Center, Division of Respiratory and Critical Care Physiology and Medicine, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA

[4] Department of Medicine, West Los Angeles VA Healthcare System, University of California, Los Angeles, CA

[5] Faculty of Biological Sciences, University of Leeds, Leeds, UK

* These authors contributed equally

Correspondence

Harry B. Rossiter, PhD

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

1124 W. Carson St., CDCRC Building, Torrance, CA 90254

Tel: 310 222 8200

Email: hrossiter@ucla.edu

ABSTRACT

Purpose: Chronic obstructive pulmonary disease (COPD) is associated with altered metabolism and body composition that accompany poor outcomes. We aimed to determine whether metabolic derangements in COPD are associated with skeletal muscle deconditioning and/or physical inactivity, independent of pulmonary obstruction.

Methods: We characterized serum metabolites associated with muscle oxidative capacity or physical activity in 44 COPD patients (FEV_1=61±4%predicted) and 63 current and former smokers with normal spirometry (CON) (FEV_1=93±2%predicted). Medial *gastrocnemius* oxidative capacity was assessed at rest from the recovery rate constant (*k*) of muscle oxygen consumption using near-infrared spectroscopy. Step counts and physical activity (average vector magnitude units (VMU)/min) were measured over 5-7 days using triaxial accelerometry. Untargeted prime and lipid metabolites were measured using liquid chromatography and mass spectrometry.

Results: Muscle *k* (1.12±0.05 vs. 1.68±0.06min^{-1}; P<0.0001; d=1.58) and VMU/min (170±26 vs. 450±50 VMU/min; P=0.004; d=1.04) were lower in severe COPD (FEV_1<50%predicted, n=14-16) compared with CON (n=56-60). 129 prime metabolites and 470 lipids with known identity were quantified. Using sex as a covariate, lipidomics revealed 24 differentially expressed lipids (19 sphingomeylins) in COPD, consequent to a diminished sex difference of sphingomeylins in COPD (FDR<0.05; n=44). Total, and some individual, fatty acid concentrations were greater in severe COPD than CON (FDR<0.05; n=16; d=0.56-1.02). After adjusting for FEV_1%predicted, we observed that grouped diacylglycerides (ρ=-0.745; FDR=0.03) and triacylglycerides (ρ=-0.811; FDR=0.01) were negatively associated with muscle oxidative capacity, but not physical activity, in severe COPD (n=14). **Conclusion**: Strong negative associations relate impaired mitochondrial function to the accumulation of serum aclyglycerides in severe COPD.

Key Words: metabolomics, mitochondria, physical activity, sphingomyelin, fatty acid

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation, mucus hypersecretion, and pulmonary emphysema; each contributing to expiratory flow limitation. Unifying symptoms of these heterogeneous phenotypes are dyspnea on exertion and exercise intolerance. Exercise intolerance and physical inactivity, not pulmonary obstruction, are the strongest predictors of mortality in COPD (1). Although no therapies beyond smoking cessation are yet proven to slow disease progression or reduce mortality, pulmonary rehabilitation - a multidisciplinary program that includes exercise training - is the most effective treatment in releveling symptoms, increasing quality of life, reducing hospitalizations and morbidity in COPD patients (2). A primary benefit of pulmonary rehabilitation in COPD is symptom relief and increased exercise tolerance, which are mediated by ameliorating skeletal muscle deficits in oxidative capacity, thereby delaying the onset of exercise-induced metabolic acidosis and reducing the ventilatory demands for a given activity (3).

Several studies of serum metabolomics show metabolic dysregulation in COPD (4-6). Alterations in sphingolipid metabolism are common in COPD, suggesting a deficit in lipid metabolism that may contribute to smoking-induced lung damage through mitophagy-mediated necroptosis (7). Altered mitochondrial β-oxidation, tryptophan metabolism, carnitine/acylcarnitine, reduced polyunsaturated fatty acids and high oxidative stress are common findings following cigarette smoke exposure and in COPD metabolomic analyses (8). Furthermore, cigarette smoke exposure is associated with the accumulation of cytotoxic ceramides in lung epithelial cells and reduced mitochondrial respiration in skeletal muscle, resulting in insulin resistance and poor glucose tolerance (7, 9).

Muscle deconditioning following physical inactivity is associated with a reduced fraction of whole-body ATP turnover that is derived from mitochondrial β-oxidation during rest or exercise

(10). Loss of mitochondrial oxidative capacity in skeletal muscle is, therefore, a primary variable implicated in mediating the association between hyperlipidemia and COPD. As both physical activity and oxidative capacity are negatively associated with COPD severity (11), this study aimed to determine whether lipid metabolite dysregulation in COPD was associated with muscle oxidative capacity and/or physical inactivity. We hypothesized that alteration of lipid metabolites in COPD would be associated with muscle oxidative capacity, independent of pulmonary function.

METHODS

Study population

The population was drawn from the single-center Muscle Health Study, an ancillary study of COPDGene (ClinicalsTrials.gov Identifier NCT00608764). A total of 245 current or former smokers participated in the Muscle Health Study at The Lundquist Institute between 2013 and 2016. Inclusion and exclusion criteria were determined by the COPDGene study design (12). Participants were non-Hispanic White or African American, aged 45–80 years, and all had ≥10 pack-year smoking history. In addition, those with known or suspected cancer or recent (within 3 months) hospitalization were excluded. Of the 245 subjects, 107 had serum samples collected for metabolomic investigation: 44 with COPD and 63 with normal spirometry acted as controls (CON). Participants gave written informed consent to participate as approved by the Institutional Review Board at The Lundquist Institute. Data of muscle oxidative capacity and pulmonary function from these participants has been previously reported (13).

Additional methodological details are provided in supplemental digital content (SDC) (see Supplement for additional details of methods for clinical assessments, muscle oxidative capacity, prime metabolomics and lipidomics).

Clinical assessments

As part of the COPDGene study protocol, clinical data collected included demographics, vital signs, medical and smoking history, and current medications. Spirometry was performed according to American Thoracic Society guidelines (14). Lung diffusing capacity for carbon monoxide (DL_{CO}) was measured after post-bronchodilator spirometry assessment (15). Resting arterial oxygen saturation was measured using pulse oximetry (SpO_2).

Muscle oxidative capacity

Oxidative capacity of the medial *gastrocnemius* muscle (*k*) was assessed using near-infrared spectroscopy (NIRS) as described previously (16). Prior work demonstrates, using direct measurements in single muscle fibers of varied biochemical phenotypes, that *k* is directly proportional to muscle oxidative capacity (17). The average *k* of two repeat measurements is reported.

Physical activity

At the end of the visit, participants received a triaxial accelerometer (DynaPort MoveMonitor, McRoberts BV, The Hague, the Netherlands) to assess number of steps per day and physical activity reported as vector magnitude units (VMU)/min. Activity measurements were considered complete if the participant maintained at least 15 hours of wearing time per day for at least 5 of the 7 days.

Prime metabolomics and lipidomics

Blood was collected from a peripheral vein using a serum separator tube (8.5 mL, BD Vacutainer) and the serum aliquoted (1 mL) and stored at -80°C for subsequent analysis. Blood was collected typically ~3-4 hours after taking a usual breakfast. Serum samples were shipped to West Coast Metabolomics Center at the University of California for metabolomic analysis.

Statistics

For general statistics, data are presented as mean ± SEM. Baseline subject characteristics, muscle oxidative capacity and physical activity were compared by ANOVA and Dunnett's *post hoc* test using CON as the reference group (continuous variables) or chi^2-test (categorical variables). Routine metabolomics data analysis was performed with MetaboAnlyst 3.0 (www.metaboanalyst.ca). Differences in metabolite concentrations among groups were assessed by analysis of variance (ANOVA) and Fisher's LSD *post hoc* test accounting for multiple comparisons using false discovery rate (FDR). Association between muscle oxidative capacity or physical activity and metabolite concentration was initially assessed using Spearman correlation stratified for GOLD class. Subsequently, lipid metabolites were categorized into 17 metabolite classes, grouped by their chemical properties, and partial correlation performed with adjustment for FEV_1 %predicted.

All comparisons were two-sided. Effect sizes are reported as Cohen's d (d). For metabolite analyses, FDR ≤ 0.05 was considered statistically significant. For other analyses, $P \leq 0.05$ was considered statistically significant.

RESULTS

Participant demographics and clinical characteristics

The baseline characteristics of the study participants are presented in **Table 1**. Overall, 55% of the 107 participants were female, 52% were African American and 48% were non-Hispanic White. COPD patients were significantly older than CON, less likely to be current smokers, and had a greater representation of non-Hispanic White participants. There were no significant differences between the groups in sex, weight, BMI, smoking history, diabetes or hypertension. By definition, FEV_1/FVC and FEV_1 %predicted were lower in COPD than CON. DL_{CO} was significantly lower in COPD than CON, but there was no difference in resting SpO_2 between the groups (**Table 1**).

Additional analyses were made on a sub-group comprised of only severe COPD (FEV_1 < 50% predicted, n=16). This sub-population is shown separately in **Table 1**. Except for the degree of pulmonary obstruction (by definition) and a lower SpO_2 than CON (not clinically significant: 97.8±2.4 vs 96.1±0.7 %; d = 0.67), severe COPD patients had baseline characteristics that were similar to the whole COPD group (**Table 1**).

Muscle oxidative capacity and physical activity

Non-invasive measurement of the $m\dot{V}O_2$ recovery rate constant, *k*, was successful in 42 (95%) COPD and 56 (89%) CON participants. *k* was significantly lower in COPD than CON (1.32±0.07 min^{-1} vs. 1.68±0.06 min^{-1}; $P < 0.0001$; d = 0.81, **Figure 1A**), and lower still in the COPD patents with severe disease (FEV_1 <50 %predicted) (1.12 ±0.05 min^{-1}; $P < 0.0001$ vs CON; n = 14; d = 1.58) (**Figure 1A**). Forty-two (95%) COPD and 56 (89%) CON completed at least 5 days of triaxial accelerometer monitoring as designed (≥15 hours per day). Daily number of steps was not different between COPD and CON (5254±701 vs. 6188±442 steps/day, $P = 0.375$; d = 0.23) but was lower in severe COPD (3171±568 steps/day; $P = 0.010$ vs. CON; d = 1.04) (**Figure 1B**). Physical activity was not different between COPD and CON (353±43 vs. 450±50 VMU/min; $P = 0.233$; d = 0.30) but was lower in severe COPD (170±26 VMU/min; $P = 0.004$ vs. CON; d = 1.04) (**Figure 1C**).

Sex differences in serum sphingomyelin were diminished in COPD patients

Lipidomics analysis using sex as a covariate revealed 24 differentially expressed lipids between all COPD and CON (one-way ANOVA) (**Figure 2A**; FDR < 0.05; d = 0.36-1.31), of which 19 were sphingomyelins. *Post hoc* analysis showed that this effect was driven by a significant difference between males and females in the CON group (see **Table SDC 1**, for a list of metabolites and differences). In CON, sphingomyelin concentrations were generally greater in females than males, and 38 sphingomyelin species were identified significantly greater in females than in males (**Figure 2B**; FDR < 0.05; d = 0.58-1.32; **Table SDC 2**, for a list of sphingomyelins that were

177 significantly different between males and females in CON). Conversely, in COPD, only 4
178 sphingomyelins were significantly greater in females than males (**Figure 2C**; FDR < 0.05; d =
179 1.00-1.35; **see Table SDC 3**, for a list of sphingomyelins that were significantly different between
180 males and females in COPD). These data indicate that the anticipated differences in sphingomyelin
181 concentrations between the sexes were diminished in COPD patients.
182
183 **Fatty acid metabolites were increased in severe COPD patients**
184 Prime metabolomics and lipidomics analysis identified 129 prime metabolites and 470 lipids with
185 known identity in the serum of study participants. Metabolite concentrations were not significantly
186 different between COPD and CON. However, several metabolites, predominantly fatty acids, were
187 differentially expressed in severe COPD (FEV_1 < 50 %predicted; n = 16) compared with CON. In
188 lipidomics analysis, total fatty acid concentration was significantly greater in severe COPD than
189 in CON (**Figure 3A**; $P < 0.05$; d = 1.02). This was predominantly due to 4 fatty acids that were
190 significantly greater in severe COPD than in CON (**Figure 3B**; FDR < 0.05; d = 0.83-0.89). In the
191 prime metabolites, the concentrations of 7 fatty acids were significantly greater in severe COPD
192 than in CON (**Figure 3C**; FDR < 0.05; d = 0.59-1.02).
193
194 **Acylglycerides were negatively associated with muscle oxidative capacity in severe COPD**
195 Spearman correlation analysis was employed to identify whether metabolite concentrations were
196 associated with the $m\dot{V}O_2$ recovery rate constant (k) and/or physical activity. All individual
197 diacylglyceride (DG) and triacylglyceride (TG) metabolites had negative correlation with muscle
198 oxidative capacity after adjusting for FEV_1 %predicted (which incorporates adjustment for age,
199 sex, race and height (18)). There were no significant associations between TG or DG with age,
200 BMI, resting systolic or diastolic blood pressure, current smoking status, smoking history, FEV_1
201 %predicted, incidence of diabetes or hypertension, steps/day or VMU/min. Overall, 7 out of 8 DG

and 48 out of 102 TG were nominally negatively associated with muscle oxidative capacity in severe COPD (**Figure 4A**, $P < 0.05$; n = 14).

Next, lipids were grouped into 17 classes based on their characteristics, and partial correlations were re-assessed. Following adjustment for FEV_1 %predicted and correcting for FDR, we found that muscle oxidative capacity was negatively correlated with diacylglyceride concentration (ρ = -0.7447; FDR = 0.03) and triacylglyceride concentration (ρ = -0.8118; FDR = 0.01) in severe COPD patients (n = 14), but not in CON (n = 56). Neither daily steps nor physical activity were significantly associated in partial correlation with the concentrations of any metabolite group (**Figure 4B**). Adjustment of the partial correlation analysis using DL_{CO} (a slightly stronger correlate of grouped metabolites than FEV_1 %predicted), did not change the significant correlation between *k* and DG (ρ = -0.7544; FDR = 0.02) or TG (ρ = -0.8116; FDR = 0.01) in the severe COPD group (n = 14). Although there was no significant association between BMI and DG or TG, we also sought to adjust for BMI due to its potential association with hyperlipidemia. This adjustment did not substantively affect the correlation between *k* and TG (ρ = -0.7579; FDR = 0.04), although the correlation was weakened between *k* and DG (ρ = -0.6746; FDR = 0.09). There remained no association between any lipid metabolite group and any measure of physical activity after adjustment for covariates.

DISCUSSION

In this study, we conducted both prime metabolomic and lipidomics analyses in COPD patients and controls, to identify whether serum metabolites were associated with physical activity and/or muscle mitochondrial oxidative capacity. We observed: 1) 24 lipids, including 19 sphingomyelins, were differentially expressed in COPD with sex as covariant; 2) sex-dependent differences in sphingomyelin concentration in controls were diminished in COPD patients; 3) severe COPD patients (n = 16) had elevated serum total fatty acids, centered on 8 individual fatty acid

metabolites; and, 4) serum concentrations of di- and tri-acylglycerides were negatively associated with muscle oxidative capacity, and not physical activity, in severe COPD (n = 14). Previous metabolomics studies of spirometrically-defined COPD reported dysregulation in several serum metabolite classes (4-6). Here we identify that skeletal muscle deconditioning in the form of reduced muscle oxidative capacity, common in COPD, may underlie metabolic dysregulation of di- and tri-acylglycerides in patients with severe pulmonary obstruction.

Dysregulation of sphingolipid metabolism is common in patients with COPD. In an untargeted lipidomic analysis of sputum samples, Telenga *et al*. (19) demonstrated that sphingolipids, including several serum sphingomyelins, were significantly greater in smokers with COPD than those without COPD. Thirteen individual serum lipid metabolites, including one sphingomyelin, showed strong negative association with FEV_1 and inflammation in sputum. Telenga *et al*. also found that two months of smoking cessation reduced concentration of 26 sphingomyelins in both groups (19). Others have demonstrated a significant negative association between sphingomyelin metabolites and emphysema from chest CT measurements (5) or COPD exacerbation severity (7).

Consistent with studies of healthy subjects (20), our data showed greater serum sphingomyelin concentration in females than in males in our control group, which consisted of current or former smokers with normal spirometry. We found that this sex difference was diminished in all COPD patients, suggesting a sex-dependent alteration of sphingomyelin metabolism in COPD. Intracellular ceramide concentration is regulated by sphingolipid metabolism and is implicated in cigarette smoking induced mitophagy (7). Sphingolipid metabolism was also associated with emphysema progression in sub-phenotyping analysis (21). Whether the diminishing sex-differences in circulating sphingomyelin metabolism underlie the more rapid progression of COPD observed in women than in men deserves further attention.

We identified that the serum concentration of total fatty acids, and some individual fatty acids, were significantly greater in severe COPD (n = 16) than in controls (n = 63). This observation was in contrast with a small study of COPD (including 10 patients with severe COPD) by Wada *et al.* where total free fatty acid concentration was significantly lower in COPD than in healthy controls (22). This discrepancy may reflect the disease stage of the subjects in each study; BMI in the severe COPD patients in the study of Wada *et al*. was significantly lower than controls, while there was no difference in BMI between groups in our study.

The role of individual circulating fatty acids in the progression of pulmonary, cardiovascular or metabolic disease in COPD patients is not well studied. For example, increased dietary intake of fatty acids is associated with greater expiratory flow limitation in COPD patients, while dietary intake of pentadecylic acid may improve lung function in these patients (23). We found 7 individual fatty acids in prime analysis and 4 in lipidomics that were greater in severe COPD, with 3 individual fatty acids recapitulated in both analytic approaches (myristic acid, plamitoleic acid and heptadecanoic acid). Myristic acid potentiates palmitic acid-induced lipotoxicity, likely through mitochondria-related mechanisms (24). Similar to a previous investigation (25), we found that the monounsaturated fatty acid, palmitoleic acid, was greater in severe COPD; which is associated with greater high and low density lipoprotein cholesterol (26). On the other hand, lauric acid was also increased in severe COPD in our prime analysis, which is implicated in potentially beneficial effects on cholesterol, insulin resistance and inflammation. Given the low mitochondrial oxidative capacity we found in muscles of severe COPD patients (13), and the known greater odds of cardiometabolic disease in severe COPD, the differential effects on COPD or COPD progression of the individual fatty acids identified here deserve further study.

Despite variability in the prevalence of hyperlipidemia, subclinical atherosclerosis occurs at a greater than expected prevalence in COPD, and is associated with more frequent exacerbations

(27). Regular physical activity and increased mitochondrial function are associated with lower blood lipids and triglycerides, and are protective of metabolic and cardiovascular disease (28). Therefore, identifying whether differences in physical activity and/or mitochondrial function underlie the observations of lipid metabolite dysregulation in COPD was a major thrust of this study. Overall, we did not find significant associations between lipid metabolites and either muscle oxidative capacity or physical activity when considering differences between all COPD patients and controls. However, there was a significant ceiling effect on these variables, and so we focused our analyses on severe disease (FEV_1 < 50 %predicted). In severe COPD, there was a strong negative association between muscle oxidative capacity and serum di- or tri-acylglycerides (ρ ranged -0.75 to -0.81; n = 14). These associations remained even after adjusting for false discovery rate, and FEV_1 or DL_{CO} or BMI. It was striking that physical activity (either steps/day or VMU/min; n = 16) was not significantly associated any serum lipid metabolite or metabolite group investigated. This distinction is important because it implies that mitochondrial metabolic health, rather than physical activity *per se*, may be involved in lipid dysregulation in severe COPD.

Support for this concept is found elsewhere in biology with, for example: a) no reduction in mortality in mice selectively bred for high lifelong energy expenditure, whereas rats selectively bred for endurance running capacity begets high muscle oxidative capacity and a ~40% increase in median lifespan (29); b) while high rates of physical activity are known to reduce all-cause mortality risk (30), the hazard ratio for mortality in 8,171 male veterans was reduced by ~50% when stratifying by exercise capacity compared with stratifying for physical activity (31); c) there was no survival benefit of increasing self-reported physical activity in longitudinal study of 1,270 COPD patients with a median follow-up duration of 17 years (32). On the other hand, it is well established that exercise training, as part of a pulmonary rehabilitation program, increases muscle oxidative capacity (33), reduces 1-year hospital readmission (odds ratio vs. usual care = 0.44 (95% confidence interval 0.21 – 0.91), and potentially reduces 1-year mortality (odd ratio = 0.68 (0.28

306 – 1.67)) (2), without an impact on physical activity (34); d) changes in fat free mass and exercise
307 capacity (but not physical activity) in COPD are also associated with rapid decline in health status
308 (35).
309
310 Metabolic syndrome is prevalent in COPD (36). Previous findings identified that an increase in
311 circulating triglycerides is a major risk factor for 5-year mortality in COPD patients (37).
312 Hypertriglyceridemia and systemic inflammation are independent predictors of elevated
313 plasminogen activator inhibitor-1 in COPD, a major inhibitor of fibrinolysis, associated with
314 thrombosis, obesity, insulin resistance, dyslipidemia, and premature aging; each prevalent in
315 COPD (38). Intracellular accumulation of triglycerides and other fatty acids, promote endoplasmic
316 reticulum stress, mitochondrial uncoupling and oxidative stress, which terminates in inflammation
317 and cell death (39). Perivascular adipose accumulation seems to trigger atherosclerosis and
318 hypertension, also prevalent in COPD. The association between circulating triglycerides and
319 muscle mitochondrial oxidative capacity we identified in severe COPD provides a strong
320 justification for the role of increasing physical fitness in reducing cardiovascular and metabolic
321 risk in this patient population. Our proposal is that attempts to redress lipid metabolic deficits in
322 COPD should not focus on simply diet or activity interventions, but specifically on obtaining the
323 health-related benefits associated with increasing muscle (and other tissue) mitochondrial
324 oxidative capacity.
325
326 There are several limitations to this study. The number of subjects is low, particularly in the severe
327 COPD group, which limited the statistical power to detect associations between individual lipid
328 metabolites and muscle oxidative capacity or physical activity. Diet and circadian rhythm are
329 known to regulate metabolism. Our serum samples were not collected with dietary control or at
330 the same circadian time range, both of which could influence postprandial lipid profile and
331 contribute to variation in metabolite concentrations. In addition, increased carbohydrate and fatty

acid intake are associated with worse pulmonary function (23). In attempt to mitigate this potential confounder, our findings remained after adjusting for FEV_1 %predicted. We were not able to include measurements of adiposity or analysis of systemic markers of inflammation, which could have contributed to our understanding of lipid dysregulation. The measure of muscle oxidative capacity we used is non-invasive; nevertheless, it was successful in 92% of participants and we have demonstrated this method has strong reproducibility in COPD patients (16), while others have shown good association (r = 0.61-0.74) with muscle biopsy (40).

In conclusion, we observed that 24 lipids, including 19 sphingomyelins, were increased in COPD with sex as covariant, and that sex-dependent differences in sphingomyelin concentration in controls were diminished in COPD patients. We also found that severe COPD patients had elevated serum total fatty acids, which centered on 8 individual fatty acid metabolites. These findings may in part underlie the more rapid progression of COPD observed in women than in men and the high prevalence of cardiovascular disease in COPD patients. Lipid dysregulation that was negatively associated with muscle oxidative capacity (ρ ranged -0.75 to -0.81; n = 14), and not physical activity (n = 16); a negative association which remained despite adjustment for FEV_1 %predicted, DL_{CO} or BMI. The strong negative association we identified between di- or tri-acylglycerides and muscle oxidative capacity, suggests that impaired mitochondrial function may play a role in the accumulation of serum aclyglycerides in severe COPD, and provides a strong rationale for targeting mitochondrial deficits by exercise training, or other means, to improve outcomes in this patient population.

ACKNOWLEDGEMENTS

The study was supported by Startup Research Fund of Shenzhen Technology University (R. Li); the National Institutes of Health VA MERT I01 BX00435, R01HL111437 and R01HL129727 (T. K. Hsiai); R01HL089856 and R01HL089897 (the COPDGene study); 1R01HL151452 (H. B.

Rossiter, A. Adami); National Center for Advancing Translational Sciences UCLA CTSI Grant UL1TR000124; Swiss National Science Foundation P300P3_151705 (A. Adami); Swiss National Science Foundation P300PB_167767 (A. Adami); American Thoracic Society Foundation/Breathe LA Project Grant ATS-2014-03 (H. B. Rossiter) and Pulmonary Education and Research Foundation (H. B. Rossiter).

CONFLICT OF INTEREST

The authors declare no conflict of interest. The authors declare that the results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The results of this study do not constitute endorsement by ACSM.

REFERENCES

1. Waschki B, Kirsten A, Holz O et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. *Chest*. 2011;140(2):331-42.
2. Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. *The Cochrane database of systematic reviews*. 2016;12:CD005305.
3. Maltais F, Decramer M, Casaburi R et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 2014;189(9):e15-62.
4. Bowler RP, Jacobson S, Cruickshank C et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. *American journal of respiratory and critical care medicine*. 2015;191(3):275-84.
5. Labaki WW, Gu T, Murray S et al. Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. *Scientific reports*. 2019;9(1):11367.
6. Yu B, Flexeder C, McGarrah RW, 3rd et al. Metabolomics Identifies Novel Blood Biomarkers of Pulmonary Function and COPD in the General Population. *Metabolites*. 2019;9(4).
7. Mizumura K, Justice MJ, Schweitzer KS et al. Sphingolipid regulation of lung epithelial cell mitophagy and necroptosis during cigarette smoke exposure. *FASEB journal.* 2018;32(4):1880-90.
8. Naz S, Kolmert J, Yang M et al. Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD. *The European respiratory journal*. 2017;49(6):1602322.

9. Taylor OJ, Thatcher MO, Carr ST et al. High-Mobility Group Box 1 Disrupts Metabolic Function with Cigarette Smoke Exposure in a Ceramide-Dependent Manner. *International journal of molecular sciences*. 2017;18(5):1099.
10. Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. *Cell metabolism*. 2017;25(5):1027-36.
11. Troosters T, Sciurba F, Battaglia S et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. *Respir Med*. 2010;104(7):1005-11.
12. Regan EA, Hokanson JE, Murphy JR et al. Genetic epidemiology of COPD (COPDGene) study design. *Copd*. 2010;7(1):32-43.
13. Adami A, Hobbs BD, McDonald MN, Casaburi R, Rossiter HB, for the COPDGene Investigators. Genetic variants predicting aerobic capacity response to training are also associated with skeletal muscle oxidative capacity in moderate-to-severe COPD. *Physiol Genomics*. 2018;50(9):688-90.
14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319-38.
15. Graham BL, Brusasco V, Burgos F et al. Executive Summary: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *The European respiratory journal*. 2017;49(1):16E0016.
16. Adami A, Cao R, Porszasz J, Casaburi R, Rossiter HB. Reproducibility of NIRS assessment of muscle oxidative capacity in smokers with and without COPD. *Respiratory physiology & neurobiology*. 2017;235:18-26.
17. Wust RC, van der Laarse WJ, Rossiter HB. On-off asymmetries in oxygen consumption kinetics of single Xenopus laevis skeletal muscle fibres suggest higher-order control. *The Journal of physiology*. 2013;591(3):731-44.

18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *American journal of respiratory and critical care medicine*. 1999;159(1):179-87.
19. Telenga ED, Hoffmann RF, Ruben tK et al. Untargeted lipidomic analysis in chronic obstructive pulmonary disease. Uncovering sphingolipids. *American journal of respiratory and critical care medicine*. 2014;190(2):155-64.
20. Rauschert S, Uhl O, Koletzko B et al. Sex differences in the association of phospholipids with components of the metabolic syndrome in young adults. *Biology of sex differences*. 2017;8:10.
21. Ahmed FS, Jiang XC, Schwartz JE et al. Plasma sphingomyelin and longitudinal change in percent emphysema on CT. The MESA lung study. *Biomarkers.* 2014;19(3):207-13.
22. Wada H, Goto H, Saitoh E et al. Reduction in plasma free fatty acid in patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 2005;171(12):1465.
23. Jimenez-Cepeda A, Davila-Said G, Orea-Tejeda A et al. Dietary intake of fatty acids and its relationship with FEV1/FVC in patients with chronic obstructive pulmonary disease. *Clinical nutrition ESPEN*. 2019;29:92-6.
24. Martinez L, Torres S, Baulies A et al. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis. *Oncotarget*. 2015;6(39):41479-96.
25. Kompauer I, Demmelmair H, Koletzko B, Bolte G, Linseisen J, Heinrich J. Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults. *Eur J Epidemiol.* 2008;23(3):175-90.
26. Nestel P, Clifton P, Noakes M. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. *J Lipid Res*. 1994;35(4):656-62.

27. Domenech A, Munoz-Montiel A, Garcia-Casares N et al. High risk of subclinical atherosclerosis in COPD exacerbator phenotype. *Respir Med*. 2018;141:165-71.
28. Leermakers PA, Gosker HR. Skeletal muscle mitophagy in chronic disease: implications for muscle oxidative capacity? *Current opinion in clinical nutrition and metabolic care*. 2016;19(6):427-33.
29. Koch LG, Britton SL, Wisloff U. A rat model system to study complex disease risks, fitness, aging, and longevity. *Trends Cardiovasc Med*. 2012;22(2):29-34.
30. Ekelund U, Tarp J, Steene-Johannessen J et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. *BMJ*. 2019;366:l4570.
31. Davidson T, Vainshelboim B, Kokkinos P, Myers J, Ross R. Cardiorespiratory fitness versus physical activity as predictors of all-cause mortality in men. *Am Heart J*. 2018;196:156-62.
32. Vaes AW, Garcia-Aymerich J, Marott JL et al. Changes in physical activity and all-cause mortality in COPD. *The European respiratory journal*. 2014;44(5):1199-209.
33. Maltais F, LeBlanc P, Simard C et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*. 1996;154(2 Pt 1):442-7.
34. Mesquita R, Meijer K, Pitta F et al. Changes in physical activity and sedentary behaviour following pulmonary rehabilitation in patients with COPD. *Respir Med*. 2017;126:122-9.
35. Rodrigues FM, Demeyer H, Loeckx M et al. Health status deterioration in subjects with mild to moderate airflow obstruction, a six years observational study. *Respir Res*. 2019;20(1):93.
36. Marquis K, Maltais F, Duguay V et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil*. 2005;25(4):226-32; discussion 33-4.

37. Tanni SE, Zamuner AT, Coelho LS, Vale SA, Godoy I, Paiva SA. Are metabolic syndrome and its components associated with 5-year mortality in chronic obstructive pupmonary disease patients? *Metab Syndr Relat Disord*. 2015;13(1):52-4.
38. Waschki B, Watz H, Holz O et al. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. *Int J Chron Obstruct Pulmon Dis*. 2017;12:981-7.
39. Ferrara D, Montecucco F, Dallegri F, Carbone F. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. *J Cell Physiol*. 2019;234(12):21630-41.
40. Ryan TE, Brophy P, Lin CT, Hickner RC, Neufer PD. Assessment of in vivo skeletal muscle mitochondrial respiratory capacity in humans by near-infrared spectroscopy: a comparison with in situ measurements. *The Journal of physiology*. 2014;592(15):3231-41.

FIGURE LEGENDS

Figure 1. Muscle oxidative capacity and physical activity is reduced in severe COPD patients compared with controls (CON). A) Muscle oxygen consumption recovery rate constant (k, min^{-1}), which is linearly proportional to muscle oxidative capacity (CON n=56; ALL COPD n=42; severe COPD n=14). **B**) Daily steps (CON n=56; ALL COPD n=42; severe COPD n=16). **C**) Average daily VMU/min (CON n=56; ALL COPD n=42; severe COPD n=16).

Figure 2. The sex difference of serum sphingomyelin concentration was diminished in COPD patients compared with controls (CON). (A) ANOVA of lipidomics of COPD patients (n=44) and CON (n=63) with sex as a covariant. Filled red circles indicate metabolites with significant difference among groups. **(B)** Comparison of sphingomyelin (SM) concentration between male and female CON subjects (n=63). **(C)** Comparison of sphingomyelin (SM) concentration between male and female COPD patients (n=44). Filled pink circles indicate metabolites with significant difference between the sexes. Data were corrected for false discovery rate (FDR).

Figure 3. Fatty acids were increased in severe COPD patients compared with controls. Lipid metabolites in severe COPD patients (FEV_1 < 50% predicted, open symbols/open bars) compared with CON (filled symbols/filled bars). **(A)** Total fatty acids were significantly greater in severe COPD patients compared with CON in lipidomics analysis. **(B)** Four fatty individual acids were identified as significantly greater in severe COPD patients in lipidomics analysis. **(C)** Seven fatty acids were identified as significantly greater in severe COPD patients in prime metabolite analysis. Data were corrected for false discovery rate (FDR): * FDR<0.05; ** FDR<0.01; *** FDR< 0.005; **** FDR<0.001; CON n=63; severe COPD n=16.

Figure 4. Diacylglyceride (DG) and triacylglyceride (TG) classes of lipid metabolites were correlated with muscle oxidative capacity in severe COPD. (A) Spearman correlation analysis of 470 individual lipid metabolites with muscle oxidative capacity in severe COPD. Individual metabolites were placed into classes based on their characteristics, shown in panel B. **(B)** Partial correlation of grouped lipid metabolites with muscle oxidative capacity, daily steps and physical activity (VMU/min). Data were adjusted for FEV_1 % predicated and corrected for FDR. Statistically significant associations were identified for DG and TG classes (panel B). DG and TG regions within the individual metabolite data are highlighted in panel A by horizontal dash. * FDR<0.05. Severe COPD n=14-16.

LIST OF SUPPLEMENTAL DIGITAL CONTENT (SDC)

1. Supplemental methods
2. Supplemental Table SDC 1
3. Supplemental Table SDC 2
4. Supplemental Table SDC 3

Fig. 1


A
p<0.0001
p<0.001
Muscle $\dot{V}O_2$ recovery rate constant (k, min^{-1})
3.0
2.5
2.0
1.5
1.0
0.5
0.0
CON
ALL COPD
Severe COPD
B
p=0.001
p=0.116
Daily steps
30000
15000
10000
5000
0
CON
ALL COPD
Severe COPD
C
p=0.004
p=0.111
VMU/min (daily average)
3000
1500
1250
1000
750
500
250
0
CON
ALL COPD
Severe COPD

Figure 2


A
One-way ANOVA: COPD vs CON
-Log10(p-value)
Compounds
B
SM levels in CON: Male vs Female
-Log10(p-value)
Compounds
C
SM levels in COPD: Male vs Female
-Log10(p-value)
Compounds

Figure 3


A
p<0.05
Levels of Total Fatty Acid (x10^6)
4
3
2
1
0
CON
Severe COPD
B
Serum levels of fatty acid-lipidomics
150000
100000
50000
10000
5000
0
*
Myristic acid
Physeteric acid
Palmitoleic acid
Heptadecanoic acid
C
Serum levels of fatty acid-prime
100000
75000
50000
25000
10000
5000
0
****
***
*
Myristic acid
Palmitoleic acid
Palmitic acid
Salicylic acid
Linoleic acid
Lauric acid
Heptadecanoic acid



Cer, ceramides; E.PE, ether phosphatidyl ethanolamines; FFA, fatty acids; GlcCer, glucosylceramides; L.PC, lysophosphatidyl cholines; L.PE, lysophosphatidyl ethanolamines; PC, phospatidyl cholines; PE, phospatidyl ethanolamines; PI, phospatidyl inositols; SM, sphyngomyelins; A-CN, acylcarnitines; CE, cholesterol esters; TC, cholesterol; DG, diacylglicerides; E.PC, ether phosphatidyl cholines; LacCer, lactosylceramides; TG, triacylglycerides

Table 1. Participant characteristics.

	Unit	CON	ALL COPD	Severe COPD	p value ALL COPD vs CON	p value Severe COPD vs CON
Number of Subjects	n	63	44	16	-	-
GOLD 1/2/3/4	n	0 / 0 / 0 / 0	14 / 14 / 9 / 7	9 / 7	-	-
Age	years	61.2 ± 1.3	65.6 ± 1.4	66.6 ± 1.6	0.039	0.086
Sex, M / F	n	29 / 34	21 / 23	6 / 10	0.981	0.786
Race, NHW / AA	n	21 / 42	30 / 14	13 / 3	<0.0001	<0.001
Weight	kg	85.3 ± 2.7	79.2 ± 2.6	78.1 ± 4.7	0.209	0.330
BMI	kg/m^2	29.8 ± 0.9	28.2 ± 0.9	29.2 ± 1.8	0.405	0.941
Smoking history	pack-years	39.2 ± 2. 6	46.5 ± 3.6	47.0 ± 6.4	0.187	0.372
Smoking duration	years	35.6 ± 1.3	37.2 ± 1.5	35.4 ± 2.7	0.656	0.997
Current smoker	n (%)	34 (54)	13 (30)	3 (13)	0.020	0.018
FEV_1/FVC	%	79.6 ± 0.7	52.5 ± 2.4	35.8 ± 3.3	<0.0001	<0.0001
FEV_1 % predicted	%	93.4 ± 2.2	61.4 ± 4.1	31.6 ± 2.9	<0.0001	<0.0001
DL_{CO}	mL/min/mmHg	75.9 ± 2.2	61.3 ± 3.6	41.8 ± 3.9	0.001	<0.0001
Diabetes	n (%)	13 (21)	4 (9)	1 (6)	0.181	0.265
Hypertension	n (%)	36 (57)	21 (48)	8 (50)	0.557	0.844
SpO_2	%	97.8 ± 2.4	97.3 ± 2.0	96.1 ± 0.7	0.421	0.015

GOLD, global initiative for obstructive lung disease spirometric classification (1, Mild; 2, Moderate; 3, Severe; 4, Very-severe); NHW, non-Hispanic White; AA, African American; BMI, body mass index; FEV_1, forced expiratory volume in 1 second; FVC, forced vital capacity; DL_{CO}, diffusing capacity for carbon monoxide; SpO_2, oxyhemoglobin saturation by pulse oximetry. Spirometric variables are post-bronchodilator values.